Update on antifungal drug resistance mechanisms of Aspergillus fumigatus

Drug Resistance Updates

Volumn 8, Issue 6, 2005, Pages 344-358

  Chamilos, G ^a   Kontoyiannis, D P ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Amphotericin B; Aspergillus fumigatus; Drug resistance; Susceptibility testing; Triazoles

Indexed keywords

ALLYLAMINE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; ITRACONAZOLE; MICAFUNGIN; NYSTATIN; POLYENE; POSACONAZOLE; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CROSS RESISTANCE; DRUG RESISTANCE; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR BIOLOGY; MYCOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 33644832215     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2006.01.001     Document Type: Article

References (126)

1. O.C. Abraham, E.K. Manavathu, J.L. Cutright, and P.H. Chandrasekar In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B Diagn. Microbiol. Infect. Dis. 33 1999 7 11
2. D.B. Archer, and P.S. Dyer From genomics to post-genomics in Aspergillus Curr. Opin. Microbiol. 7 2004 499 504
3. S.A. Balajee, and K.A. Marr Conidial viability assay for rapid susceptibility testing of Aspergillus species J. Clin. Microbiol. 40 2002 2741 2745
4. S.A. Balajee, M. Weaver, A. Imhof, J. Gribskov, and K.A. Marr Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals Antimicrob. Agents Chemother. 48 2004 1197 1203
5. Balajee, S.A., Hanley, E., Imhof, A., Fredricks, D., Brandt, M.E., Warnock, D.W., et al., 2004b. Aspergillus fumigatus isolates with decreased susceptibility to multiple antifungals: a variant or a newly identified species? 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, Abstract # M-1676.
6. S.A. Balajee, J.L. Gribskov, E. Hanley, D. Nickle, and K.A. Marr Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus Eukaryot. Cell 4 2005 625 632
7. S.A. Balajee, J. Gribskov, M. Brandt, J. Ito, A. Fothergill, and K.A. Marr Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus J. Clin. Microbiol. 43 2005 5996 5999
8. S.V. Balashov, R. Gardiner, S. Park, and D.S. Perlin Rapid, high-throughput, multiplex, real-time PCR for identification of mutations in the cyp51A gene of Aspergillus fumigatus that confer resistance to itraconazole J. Clin. Microbiol. 43 2005 214 222
9. A. Beauvais, and J.P. Latgé Membrane and cell wall targets in Aspergillus fumigatus Drug Resist. Updat. 4 2001 38 49
10. D. Caillot, H. Bassaris, A. McGeer, C. Arthur, H.G. Prentice, W. Seifer, and K. De Beule Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS Clin. Infect. Dis. 38 2001 83 90
11. J.O. Capobianco, D. Zakula, D.J. Frost, R.C. Goldman, L. Li, L.L. Klein, and P.A. Lartey Cellular accumulation, localization, and activity of a synthetic cyclopeptamine in fungi Antimicrob. Agents Chemother. 42 1998 389 393
12. E. Chryssanthou In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole Scand. J. Infect. Dis. 29 1997 509 512
13. J. Chen, L. Houmin, L. Ruoyu, B. Dinfang, and W. Zhe Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma J. Antimicrob. Chemother. 55 2005 31 37
14. T.M. Chiller, and D.A. Stevens Treatment strategies for Aspergillus infections Drug Resist. Updat. 3 2000 89 97
15. L.E. Cowen, and S. Lindquist Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi Science 309 2005 2185 2189
16. E. Dannaoui, E. Borel, M.F. Monier, M.A. Piens, S. Picot, and F. Persat Acquired itraconazole resistance in Aspergillus fumigatus J. Antimicrob. Chemother. 47 2001 333 340
17. E. Dannaoui, J. Meletiadis, A.M. Tortorano, F. Symoens, N. Nolard, M.A. Viviani, M.A. Piens, B. Lebeau, P.E. Verweij, R. Grillot EBGA Network Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients J. Med. Mycrobiol. 53 2004 129 134
18. M.E. da Silva Ferreira, J.L. Capellaro, E. dos Reis Marques, I. Malavazi, D. Perlin, and S. Park In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance Antimicrob. Agents Chemother. 48 2004 4405 4413
19. D.W. Denning, S.A. Radford, K.L. Oakley, L. Hall, E.M. Johnson, and D.W. Warnock Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection J. Antimicrob. Chemother. 40 1997 401 414
20. D.W. Denning, K. Venkateswarlu, K.L. Oakley, M.J. Anderson, N.J. Manning, D.A. Stevens, D.W. Warnock, and S.L. Kelly Itraconazole resistance in Aspergillus fumigatus Antimicrob. Agents Chemother. 41 1997 1364 1368
21. D.W. Denning, and P. Warn Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B Antimicrob. Agents Chemother. 43 1999 2592 2599
22. D.W. Denning, P. Ribaud, N. Milpied, D. Caillot, R. Herbrecht, E. Thiel, A. Haas, M. Ruhnke, and H. Lode Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin. Infect. Dis. 34 2002 563 571
23. T.M. Diaz-Guerra, E. Mellado, M. Cuenca-Estrella, and J.L. Rodriguez-Tudela A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus Antimicrob. Agents Chemother. 47 2003 1120 1124
24. A. Espinel-Ingroff, A. Fothergill, J. Peter, M. Rinaldi, and T.J. Walsh Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: CLSI collaborative study J. Clin. Microbiol. 40 2002 3204 3208
25. A. Espinel-Ingroff Utility of mould susceptibility testing Curr. Opin. Infect. Dis. 16 2003 527 532
26. A. Espinel-Ingroff Evaluation of broth microdilution testing parameters and agar diffusion Etest procedure for testing susceptibilities of Aspergillus spp. to caspofungin acetate (MK-0991) J. Clin. Microbiol. 41 2003 403 409
27. J.E. Galagan, S.E. Calvo, C. Cuomo, L.J. Ma, J.R. Wortman, and S. Batzoglou Sequencing of Aspergillus nidulans and comparative analysis with A. fumigatus and A. oryzae Nature 438 2006 1105 1115
28. Garcia-Effron, G., Mellado, E., Alcazar-Fuoli, L., Buitrago, M.J., Cuenca-Estrella, M., Rodriguez-Tudela, J.L., 2005. Role of Aspergillus fumigatus 14-alpha sterol demethylase (Cyp51b) gene on cell growth and viability, antifungal susceptibility and sterol composition. In 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, Abstract # M-1591.
29. R.E. Gardiner, P. Souteropoulos, S. Park, and D.S. Perlin Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin Med. Mycol. 43 2005 S299 S305
30. A. Gehrt, J. Peter, P.A. Pizzo, and T.J. Walsh Effect of increasing inoculum sizes of pathogenic filamentous fungi on MICs of antifungal agents by broth microdilution method J. Clin. Microbiol. 33 1995 1302 1307
31. M.A. Graminha, M.F. Rocha, R.A. Prade, and N.M. Martinez-Rossi Terbinafine resistance mediated by salicylate 1-monooxygenase in Aspergillus nidulans Antimicrob. Agents Chemother. 48 2004 3530 3535
32. A.H. Groll, and H. Kolve Antifungal agents: in vivo susceptibility testing, pharmacodynamics, and prospects for combination therapy Eur. J. Clin. Infect. Dis. 23 2004 256 270
33. J. Guarro, C. Llop, C. Aguilar, and I. Pujol Comparison of in vivo antifungal susceptibilities of conidia and hyphae of filamentous fungi Antimicrob. Agents Chemother. 41 1997 2760 2762
34. Guinea, J., Pelaez, T., Alcala, L., Bouza, E., 2005. Extended loss of susceptibility in Aspergillus fumigatus; analysis of 596 strains. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, Abstract # M-1609.
35. R.Y. Hachem, D.P. Kontoyiannis, M.R. Boktour, C. Afif, C. Cooksley, and G.P. Bodey Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies Cancer 101 2004 1594 1600
36. I. Hapala, V. Klobucnikova, K. Mazanova, and P. Kohut Two mutants selectively resistant to polyenes reveal distinct mechanisms of antifungal activity by nystatin and amphotenicin B Biochem. Soc. Trans. 33 2005 1206 1209
37. R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, and J.W. Oestmann Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N. Engl. J. Med. 347 2002 408 415
38. Herbrecht, R., Marr, K., Catanzaro, A., Greenberg, R., Tissot-Dupont, H., Gallais, H., Moore, T., Corcoran, G., Pedicone, L., 2005. Posaconazole as salvage therapy for invasive fungal infections unresponsive to voriconazole: a case series. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, Abstract # M-1044.
39. P.R. Hsueh, Y.J. Lau, Y.C. Chuang, J.H. Wan, W.K. Huang, and J.M. Shyr Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003 Antimicrob. Agents Chemother. 49 2005 512 517
40. M. Hosseini-Yeganeh, and A.J. Mc Lachlan Physiologically based pharmacokinetic model for terbinafine in rats and humans Antimicrob. Agents Chemother. 46 2002 2219 2228
41. A. Imhof, S.A. Balajee, and K.A. Marr New methods to assess susceptibilities of Aspergillus isolates to caspofungin J. Clin. Microbiol. 41 2003 5683 5688
42. E.M. Johnson, K.L. Oakley, S.A. Radford, C.B. Moore, P. Warn, D.W. Warnock, and D.W. Denning Lack of correlation of in vivo amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection J. Antimicrob. Chemother. 45 2000 85 93
43. N. Kartsonis, J. Nielsen, and C.M. Douglas Caspofungin: the first in a new class of antifungal agents Drug Resist. Updat. 6 2003 197 218
44. S.L. Kelly, D.C. Lamb, M. Taylor, A.J. Corran, B.C. Baldwin, and W.G. Powderly Resistance to amphotericin B associated with defective sterol delta 8-7 isomerase in a Cryptococcus neoformans strain from an AIDS patient FEMS Microbiol. Lett. 122 1994 39 42
45. A. Kolaczkowska, and A. Goffeau Regulation of pleiotropic drug resistance in yeast Drug Resist. Updat. 2 1999 403 414
46. D.P. Kontoyiannis, N. Sagar, and K.D. Hirschi Ovrexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae Antimicrob. Agents Chemother. 43 1999 2798 2800
47. D.P. Kontoyiannis, R.E. Lewis, N. Sagar, R.A. Prince, and K.V. Rolston Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy Antimicrob. Agents Chemother. 44 2000 2915 2918
48. D.P. Kontoyiannis Why prior fluconazole use is associated with an increased risk of invasive mold infections in immunosuppressed hosts: an alternative hypothesis Clin. Infect. Dis. 34 2002 1281 1283
49. D.P. Kontoyiannis, and G.P. Bodey Invasive aspergillosis in 2002: an update Eur. J. Clin. Microbiol. Infect. Dis. 21 2002 161 172
50. D.P. Kontoyiannis, and R.E. Lewis Antifungal drug resistance of pathogenic fungi Lancet 359 2002 1135 1144
51. D.P. Kontoyiannis, R.E. Lewis, G.S. May, N. Osherov, and M.G. Rinaldi Aspergillus nidulans is frequently resistant to amphotericin B Mycoses 45 2002 406 407
52. D. Lamb, D. Kelly, and S. Kelly Molecular aspects of azole antifungal action and resistance Drug Resist. Updat. 2 1999 390 402
53. K. Langfelder, S. Gattung, and A.A. Brakhage A novel method used to delete a new Aspergillus fumigatus ABC transporter gene Curr. Genet. 41 2002 268 274
54. C. Lass-Flörl, G. Kofler, G. Kropshofer, J. Hermans, A. Kreczy, M.P. Dierich, and D. Niederwieser In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis J. Antimicrob. Chemother. 42 1998 497 502
55. C. Lass-Flörl, C. Speth, G. Kofler, M.P. Dierch, E. Gunsilius, and R. Wurzner Effect of increasing inoculum sizes of Aspergillus hyphae on MICs and MFCs of antifungal agents by broth microdilution method Int. J. Antimicrob. Chemother. 21 2003 229 233
56. J.P. Latge, I. Mouyna, F. Tekaia, A. Beauvais, J.P. Debeaupuis, and W. Nierman Specific molecular features in the organization and biosynthesis of the cell wall of Aspergillus fumigatus Med. Mycol. 43 2005 S15 S22
57. R.E. Lewis, R.A. Prince, J. Chi, and D.P. Kontoyiannis Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis Antimicrob. Agents Chemother. 46 2002 3208 3214
58. M.S. Lionakis, R.E. Lewis, H.A. Torres, N.D. Albert, I.I. Raad, and D.P. Kontoyiannis Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for Aspergilli Diagn. Microbiol. Infect. Dis. 52 2005 15 20
59. M.S. Lionakis, R.E. Lewis, G. Chamilos, and D.P. Kontoyiannis Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: difficulties in establishing correlation between in vivo susceptibility data and the outcome of initial amphotericin B therapy Pharmacotherapy 25 2005 1174 1180
60. W. Liu, M. Lionakis, R.E. Lewis, N. Wiederhold, G.S. May, and D.P. Kontoyiannis Attenuation of itraconazole fungicidal activity following preexposure of Aspergillus fumigatus to fluconazole Antimicrob. Agents Chemother. 47 2003 3592 3597
61. W. Liu, G. May, M. Lionakis, R.E. Lewis, and D.P. Kontoyiannis Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus Antimicrob. Agents Chemother. 48 2004 2490 2496
62. M. Machida, K. Asai, M. Sano, T. Tanaka, T. Kumagai, and G. Terai Genome sequencing and analysis of Aspergillus oryzae Nature 438 2006 1157 1161
63. J. Maertens, I. Raad, G. Petrikkos, M. Boogaerts, D. Selleslag, and F.B. Petersen Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy Clin. Infect. Dis. 39 2004 1563 1571
64. E. Martin-Mazuelos, J. Peman, A. Valverde, M. Chaves, M.C. Serrano, and E. Cantoin Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the CLSI M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp J. Antimicrob. Chemother. 52 2003 365 370
65. E.K. Manavathu, G.J. Alangaden, and P.H. Chandrasekar In-vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus J. Antimicrob. Chemother. 41 1998 615 619
66. E.K. Manavathu, J. Cutright, and P.H. Chadrasekar Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents J. Clin. Microbiol. 37 1999 858 861
67. E.K. Manavathu, J.A. Vazquez, and P.H. Chandrasekar Reduced susceptibility in laboratory-selected mutants of Aspergillus fumigatus to itraconazole due to decreased intracellular accumulation of the antifungal agent Int. J. Antimicrob. Agents. 12 1999 213 219
68. E.K. Manavathu, J.L. Cutright, D. Loebenberg, and P.H. Chandrasekar A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592) J. Antimicrob. Chemother. 46 2000 229 234
69. E.K. Manavathu, O.C. Abraham, and P.H. Chandrasekar Isolation and in vivo susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus Clin. Microbiol. Infect. 7 2001 130 137
70. E.K. Manavathu, J.L. Cutright, and P.H. Chandrasekar In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B Antimicrob. Agents Chemother. 49 2005 428 430
71. P.A. Mann, R.M. Parmegiani, S.Q. Wei, C.A. Mendrick, X. Li, and D. Loebenberg Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase Antimicrob. Agents Chemother. 47 2003 557 581
72. J. Meletiadis, D.T.A. Dorsthorst, and P.E. Verweij Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi J. Clin. Microbiol. 41 2003 4718 4725
73. E. Mellado, T.M. Diaz-Guerra, M. Cuenca-Estrella, and J.L. Rodriguez-Tudela Identification of two different 14-alpha sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species J. Clin. Microbiol. 39 2001 2431 2438
74. E. Mellado, G. Garcia-Effron, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J.L. Rodriguez-Tudela Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs Antimicrob. Agents Chemother. 48 2004 2747 2750
75. Mellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Wolfs, T., Verweij, P.E., Cuenca-Estrella, M., Rodriguez-Tudela, J.L., 2005a. A new resistance mechanism to azole drugs in multiple isolates of Aspergillus fumigatus. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, Abstract # M-1581.
76. Mellado, E., Alcazar-Fuoli, L., Garcia-Effron, G., Cuenca-Estrella, M., Rodriguez-Tudela, J.L., 2005b. Functional analysis of Aspergillus fumigatus C-5 sterol desaturases (ERGA and ERGB) genes. In: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA, Abstract # M-1590.
77. I. Meneau, and D. Sanglard Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates Med. Mycol. 43 2005 S307 S310
78. W.G. Mertz, D. Fay, B. Thumar, and D. Dixon Susceptibility testing of filamentous fungi to amphotericin B by a rapid radiometric method J. Clin. Microbiol. 19 1984 54 56
79. J. Mosquera, and D.W. Denning Azole cross-resistance in Aspergillus fumigatus Antimicrob. Agents Chemother. 46 2002 556 557
80. J. Mosquera, P.A. Warn, J. Morrissey, C.B. Moore, C. Gil-Lamaignere, and D.W. Denning Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo Antimicrob. Agents Chemother. 45 2001 1456 1462
81. C.B. Moore, N. Sayers, J. Mosquera, J. Slaven, and D.W. Denning Antifungal drug resistance in Aspergillus J. Infect. 41 2000 203 220
82. C.B. Moore, C.M. Walls, and D.W. Denning In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B Antimicrob. Agents Chemother. 44 2000 441 443
83. M.Y. Moosa, G.J. Alangaden, E. Manavathu, and P.H. Chandrasekar Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis J. Antimicrob. Chemother. 49 2002 209 213
84. A.M. Nascimento, G.H. Goldman, S. Park, S.A. Marras, G. Delmas, and U. Oza Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole Antimicrob Agents Chemother. 47 2003 1719 1726
85. W.C. Nierman, A. Pain, M.J. Anderson, J.R. Wortman, H.S. Kim, and J. Arroyo Genome sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus Nature 438 2006 1151 1156
86. NCCLS Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, M27-A2 second ed. 2002 National Committee for Clinical Laboratory Standards Wayne, PA
87. NCCLS Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A 2002 National Committee for Clinical Laboratory Standards Wayne, PA
88. K.L. Oakley, C.B. Moore, and D.W. Denning In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp Antimicrob. Agents Chemother. 41 1997 1504 1507
89. F.C. Odds Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? Drug Resist. Updat. 1 1998 11 15
90. F.C. Odds, A.J. Brown, and N.A. Gow Antifungal agents: mechanisms of action Trends Microbiol. 11 2003 279 299
91. F. Offner, V. Krcmery, M. Boogaerts, C. Doyen, D. Engelhard, and P. Ribaud Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B Antimicrob. Agents Chemother. 48 2004 4808 4812
92. N. Osherov, D.P. Kontoyiannis, A. Romans, and G.S. May Resistance to itraconazole in Aspergillus nidulans and Aspergillus fumigatus is conferred by extra copies of the A. nidulans P-450 14alpha-demethylase gene, pdmA J. Antimicrob. Chemother. 48 2001 75 81
93. T.F. Patterson New agents for treatment of invasive aspergillosis Clin. Infect. Dis. 35 2002 367 369
94. P.J. Paterson, S. Seaton, H.G. Prentice, and C.C. Kibbler Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B J. Antimicrob. Chemother. 52 2003 873 876
95. J. Pavie, C. Lacroix, D.G. Hermoso, M. Robin, C. Ferry, A. Bergeron, M. Feuilhade, F. Dromer, E. Gluckman, J.M. Molina, and P. Ribaud Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis J. Clin. Microbiol. 43 2005 4902 4904
96. M.A. Pfaller, and D.J. Diekema Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus J. Clin. Microbiol. 42 2004 419 4431
97. E.M. Rocha, C.B. Almeida, and N.M. Martinez-Rossi Identification of genes involved in terbinafine resistance in Aspergillus nidulans Lett. Appl. Microbiol. 35 2002 228 232
98. N.S. Ryder Terbinafine: mode of action and properties of the squalene epoxidase inhibition Br. J. Derm. 126 1992 2 7
99. D. Sanglard, F. Ischer, D. Calabrese, M. de Micheli, and J. Bille Multiple resistance mechanisms to azole antifungals in yeast clinical isolates Drug Resist. Updat. 1 1998 255 265
100. A. Schaffner, and A. Bohler Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism Mycoses 36 1993 421 424
101. G.F. Schiraldi, S.L. Cicero, M.D. Colombo, D. Rossato, M. Ferrarese, and E. Soresi Refractory pulmonary aspergillosis: compassionate trial with terbinafine Br. J. Derm. 46 1996 25 29
102. S. Schwartz, M. Ruhnke, P. Ribaud, L. Corey, T. Driscoll, O.A. Cornely, U. Schuler, I. Lutsar, P. Troke, and E. Thiel Improved outcome in central nervous system aspergillosis, using voriconazole treatment Blood 106 2005 2641 2645
103. B.H. Segal, E.S. De Carlo, K.J. Kwon-Chung, H.L. Malech, J.I. Gallin, and S.M. Holland Aspergillus nidulans infection in chronic granulomatous disease Medicine 77 1998 345 354
104. K. Seo, H. Akiyoshi, and Y. Ohnishi Alteration of cell wall composition leads to amphotericin B resistance in Aspergillus flavus Microbiol. Immun. 43 1999 1017 1025
105. J.W. Slaven, M.J. Anderson, D. Sanglard, G.K. Dixon, J. Bille, I.S. Roberts, and D.W. Denning Increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate Fungal Genet. Biol. 36 2002 199 206
106. W.J. Steinbach, D.K. Benjamin, D.P. Kontoyiannis, J.R. Perfect, I. Lutsar, and K.A. Marr Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases Clin. Infect. Dis. 39 2004 192 198
107. W.J. Steinbach, J. Perfect, W.A. Schell, T.J. Walsh, and D.K. Benjamin In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection Antimicrob. Agents Chemother. 48 2004 3217 3225
108. T.R. Sterling, and W.G. Merz Resistance to amphotericin B: emerging clinical and microbiological patterns Drug Resist. Updat. 1 1998 161 165
109. D.A. Sutton, S.E. Sanche, S.G. Revankar, A.W. Forthergill, and M.G. Rinaldi In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole J. Clin. Microbiol. 37 1999 2343 2345
110. T. Takasuka, N.M. Sayers, M.J. Anderson, E.W. Bendow, and D.W. Denning Aspergillus fumigatus catalases: cloning of an Aspergillus nidulans catalase B homologue and evidence for at least three catalases FEMS Immunol. Med. Microbiol. 23 1999 125 133
111. J.J. Tarrand, X.Y. Han, D.P. Kontoyiannis, and G.S. May Aspergillus hyphae in infected tissue: evidence of physiologic adaptation and effect on culture recovery J. Clin. Microbiol. 43 2005 382 386
112. F. Tekaia, and J.P. Latge Aspergillus fumigatus: saprophyte or pathogen? Curr. Opin. Microbiol. 8 2005 385 392
113. M.B. Tobin, R.B. Peery, and P.L. Skatrud Genes encoding multiple drug resistance-like proteins in Aspergillus fumigatus and Aspergillus flavus Gene 200 1997 11 23
114. P.E. Verweij, K.L. Oakley, J. Morrissey, and D.W. Denning Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis Antimicrob. Agents Chemother. 42 1998 873 878
115. P.E. Verweij, M. Mensink, A.J. Rijs, J.P. Donnelly, J.F. Meis, and D.W. Denning In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates J. Antimicrob. Chemother. 42 1998 389 392
116. P.E. Verweij, D.T. Te Dorsthorst, A.J. Rijs, H.G. De Vries-Hospers, and J.F. Meis Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998 J. Clin. Microbiol. 40 1998 2648 2650
117. T.J. Walsh, J.W. Hiemenz, N.L. Seibel, J.R. Perfect, G. Horwith, L. Lee, J.L. Silber, M.J. DiNubile, A. Reboli, J. Lister, and E.J. Anaissie Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases Clin. Infect. Dis. 26 1998 1383 1396
118. T.J. Walsh, V. Petraitis, R. Petraitiene, A. Field-Ridley, D. Sutton, and M. Ghannoum Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B J. Infect. Dis. 188 2003 305 319
119. P.A. Warn, G. Morrissey, J. Morrissey, and D.W. Denning Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B J. Antimicrob. Chemother. 51 2003 913 919
120. P.A. Warn, A. Sharp, J. Guinea, and D.W. Denning Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida J. Antimicrob. Chemother. 53 2004 743 749
121. D.W. Warnock, B.A. Arthington-Skaggs, and R.K. Li Antifungal drug susceptibility testing and resistance in Aspergillus Drug Resist. Updat. 2 1999 326 334
122. A. Warris, C.M. Weemaes, and P.E. Verweij Multidrug resistance in Aspergillus fumigatus N. Engl. J. Med. 347 2002 2173 2174
123. T.C. White, K.A. Marr, and R.A. Bowden Clinical, cellular and molecular factors that contribute to antifungal drug resistance Clin. Microbiol. Rev. 11 1998 382 402
124. N.P. Wiederhold, D.P. Kontoyiannis, J. Chi, R.A. Prince, V.H. Tam, and R.A. Lewis Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity J. Infect. Dis. 190 2004 1464 1471
125. L. Xiao, V. Madison, A.S. Chau, D. Loebenberg, R.E. Palermo, and P.M. McNicolas Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding Antimicrob. Agents Chemother. 48 2004 568 574
126. Q. Xiong, S.A. Hassan, W.K. Wilson, X.Y. Han, G.S. May, J.J. Tarrand, and P.T. Matsuda Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors Antimicrob. Agents Chemother. 49 2005 518 524